ClinConnect ClinConnect Logo
Search / Trial NCT06657131

Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer

Launched by HEINRICH-HEINE UNIVERSITY, DUESSELDORF · Oct 23, 2024

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

Prostate Cancer Biochemical Recurrence 18 F Psma 1007 [18 F]Psma 1007 Biochemical Persistence

ClinConnect Summary

This clinical trial is studying a new diagnostic tool called [18F]PSMA-1007, which helps doctors detect prostate cancer that may have come back after initial treatment. The trial aims to see how well this imaging method works in everyday medical care and how it can improve the management of prostate cancer for patients. By gathering real-world evidence, the researchers hope to provide insights that will help doctors optimize treatment decisions for men facing biochemical recurrence of prostate cancer.

To participate in this study, men between the ages of 65 and 74 who can give informed consent are eligible. Participants will undergo [18F]PSMA-1007 PET imaging as part of their regular clinical care. It's important to note that those with any technical issues during the imaging process will not be included in the study. If you decide to join, you can expect to contribute valuable information that may help improve future prostate cancer diagnostics and treatments.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Informed Consent
  • Conduct of \[18F\]PSMA-1007 PET Imaging in the context of regular clinical care
  • Exclusion Criteria:
  • Technical Flaws in the acquisition protocol

About Heinrich Heine University, Duesseldorf

Heinrich-Heine University Düsseldorf is a leading academic institution dedicated to advancing medical research and education. Renowned for its innovative approach to healthcare and interdisciplinary collaboration, the university plays a pivotal role in clinical trials aimed at improving patient outcomes and translating scientific discoveries into clinical practice. With a robust infrastructure and a commitment to ethical standards, Heinrich-Heine University fosters an environment that supports cutting-edge research initiatives, contributing significantly to the advancement of medical knowledge and therapeutic interventions.

Locations

Düsseldorf, Nrw, Germany

Patients applied

0 patients applied

Trial Officials

Frederik Lars Giesel, Prof. Dr., Medical Doctor

Study Chair

Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported